According to the American Cancer Society, it is estimated that there will be about 175,000 new cases of prostate cancer diagnosed in 2019. About one out of every nine (12%) men in general will be diagnosed with prostate cancer in his lifetime, and that number rises to one in six (17%) for black or African American men specifically. Most often, prostate cancer happens sporadically, with no clear reason why the cancer started. However, sometimes prostate cancer can be seen running in a family in a hereditary manner, being passed down from generation to generation. Around 5-10% of prostate cancer diagnoses can be considered part of a hereditary cancer predisposition syndrome.
July 24, 2019
May 29, 2018
Although the terms “genetic” and “genomic” are often used interchangeably, they are actually very different. Learning more about the differences between them can help clear up some of the confusion we often see related to hereditary genes linked to developing cancer.
Genetics usually refers to the study of specific, individual genes and whether they are passed from one generation to the next. Cancer researchers have studied hereditary gene mutations (changes) that can play a role in the development of cancer.
By Mark T. Fleming, MD
Genetic testing for cancer and targeted drug therapy regimens have changed how multiple cancers, particularly breast cancer, colon cancer, and lung cancers are cared for. More and more, we are finding similar benefits in the diagnosis and treatment of prostate cancer.
High-quality genetic testing now can accurately pinpoint both hereditary and somatic mutations, providing crucial insights into how prostate cancer develops and grows. At the same time, new medications tailored to specific mutations have shown great promise in clinical trials, especially in a metastatic disease that has not responded to standard androgen-deprivation therapy.
February 16, 2018
In 2013, the US Supreme Court ruled against one company owning the patent on genetic testing for BRCA1 and BRCA2 genes. Changes in these genes are associated with a high risk for breast cancer and ovarian cancer. The ruling cited that human genes are not eligible for patents because they are a product of nature. Since this ruling, the world of cancer genetic testing has opened up both scientifically and financially.
Prior to the Supreme Court ruling, only one commercial laboratory was able to offer testing for the BRCA1 and BRCA2 genes. Since the patent has been overturned, multiple laboratories have started to offer testing for BRCA1 and BRCA2 and from this, multigene cancer panels have emerged. Multigene cancer panels allow testing for many additional genes associated with breast cancer, ovarian cancer, colon cancer, and various other cancers.